Tokyo Tape
Sign in
← GNI Group

Half-year report · Q2

2160.TEDINET S100U8GV
Period2024-01-01 → 2024-06-30
Filed2024-08-14
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥11.7bn2024-01-01 → 2024-06-30Cons.Revenue IFRS
Revenue¥5.8bn2024-04-01 → 2024-06-30dCons.Revenue IFRS
Revenue¥26.0bn2023-01-01 → 2023-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥14.1bn2023-01-01 → 2023-06-30Cons.Revenue IFRS
Revenue¥9.9bn2023-04-01 → 2023-06-30dCons.Revenue IFRS
Operating income¥1.8bn2024-01-01 → 2024-06-30Cons.Operating profit loss IFRS
Operating income−¥522m2024-04-01 → 2024-06-30dCons.Operating profit loss IFRS
Operating income¥5.5bn2023-01-01 → 2023-06-30Cons.Operating profit loss IFRS
Operating income¥5.1bn2023-04-01 → 2023-06-30dCons.Operating profit loss IFRS
Profit before tax¥831m2024-01-01 → 2024-06-30Cons.Profit loss before tax IFRS
Profit before tax−¥996m2024-04-01 → 2024-06-30dCons.Profit loss before tax IFRS
Profit before tax¥12.6bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥5.1bn2023-01-01 → 2023-06-30Cons.Profit loss before tax IFRS
Profit before tax¥5.2bn2023-04-01 → 2023-06-30dCons.Profit loss before tax IFRS
Net income (owners)¥330m2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥1.1bn2024-04-01 → 2024-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥8.1bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥1.7bn2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥1.7bn2023-04-01 → 2023-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income−¥74m2024-01-01 → 2024-06-30Cons.Profit loss IFRS
Net income−¥1.4bn2024-04-01 → 2024-06-30dCons.Profit loss IFRS
Net income¥9.5bn2023-01-01 → 2023-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥4.0bn2023-01-01 → 2023-06-30Cons.Profit loss IFRS
Net income¥4.4bn2023-04-01 → 2023-06-30dCons.Profit loss IFRS
Total assets¥69.0bnat 2024-06-30Cons.Assets IFRS
Total assets¥62.4bnat 2023-12-31Cons.Assets IFRS
Total assets¥45.1bnat 2023-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥29.4bnat 2024-06-30Cons.Liabilities IFRS
Total liabilities¥26.3bnat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥39.6bnat 2024-06-30Cons.Equity IFRS
Net assets / equity¥36.1bnat 2023-12-31Cons.Equity IFRS
Net assets / equity¥24.8bnat 2023-06-30Cons.Equity IFRS
Net assets / equity¥19.8bnat 2022-12-31dCons.Equity IFRS
Equity (owners)¥36.8bnat 2024-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥33.8bnat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥23.0bnat 2023-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥16.3bnat 2024-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥21.6bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥14.1bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.0bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥1.5bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥6.5bn2023-01-01 → 2023-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥872m2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥5.5bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥6.8bn2023-01-01 → 2023-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥2.6bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥186m2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥10.7bn2023-01-01 → 2023-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥3.9bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥6.612024-01-01 → 2024-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-22.492024-04-01 → 2024-06-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥169.52023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥34.932023-01-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥34.992023-04-01 → 2023-06-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥6.372024-01-01 → 2024-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-22.492024-04-01 → 2024-06-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥165.562023-01-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥34.812023-01-01 → 2023-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥34.882023-04-01 → 2023-06-30dCons.Diluted earnings loss per share IFRS
Equity ratio53.4%at 2024-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio54.2%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio51.0%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 22
SegmentItemPeriodValue
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue2024-01-01 → 2024-06-30¥2.6bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue external2024-01-01 → 2024-06-30¥2.6bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentsegment profit2024-01-01 → 2024-06-30¥676m
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue2024-01-01 → 2024-06-30¥9.1bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue external2024-01-01 → 2024-06-30¥9.1bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentsegment profit2024-01-01 → 2024-06-30¥1.1bn
—segment totalrevenue2024-01-01 → 2024-06-30¥11.7bn
—segment totalrevenue external2024-01-01 → 2024-06-30¥11.7bn
—segment totalsegment profit2024-01-01 → 2024-06-30¥1.8bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-06-30−¥23m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-06-30−¥23m
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue2023-01-01 → 2023-06-30¥1.4bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue external2023-01-01 → 2023-06-30¥1.3bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue intersegment2023-01-01 → 2023-06-30¥23m
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentsegment profit2023-01-01 → 2023-06-30¥512m
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue2023-01-01 → 2023-06-30¥12.8bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue external2023-01-01 → 2023-06-30¥12.8bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentsegment profit2023-01-01 → 2023-06-30¥5.0bn
—segment totalrevenue2023-01-01 → 2023-06-30¥14.1bn
—segment totalrevenue external2023-01-01 → 2023-06-30¥14.1bn
—segment totalrevenue intersegment2023-01-01 → 2023-06-30¥23m
—segment totalsegment profit2023-01-01 → 2023-06-30¥5.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 740
ItemContextValueUnit
Profit loss IFRSCurrentYTDDuration-73850000JPY
Profit loss attributable to owners of parent IFRSPrior1YTDDuration1658805000JPY
Profit loss attributable to owners of parent IFRSCurrentYTDDuration330126000JPY
Profit loss attributable to non controlling interests IFRSPrior1YTDDuration2355269000JPY
Profit loss attributable to non controlling interests IFRSCurrentYTDDuration-403976000JPY
Basic earnings loss per share IFRSPrior1YTDDuration34.93
Basic earnings loss per share IFRSCurrentYTDDuration6.61
Diluted earnings loss per share IFRSPrior1YTDDuration34.81
Diluted earnings loss per share IFRSCurrentYTDDuration6.37
Revenue IFRSPrior1QuarterDuration9890409000JPY
Revenue IFRSCurrentQuarterDuration5785252000JPY
Cost of sales IFRSPrior1QuarterDuration767856000JPY
Cost of sales IFRSCurrentQuarterDuration948697000JPY
Gross profit IFRSPrior1QuarterDuration9122552000JPY
Gross profit IFRSCurrentQuarterDuration4836554000JPY
Selling general and administrative expenses IFRSPrior1QuarterDuration3532820000JPY
Selling general and administrative expenses IFRSCurrentQuarterDuration3829056000JPY
Research and development expenditure recognized as expense during period IFRSPrior1QuarterDuration617410000JPY
Research and development expenditure recognized as expense during period IFRSCurrentQuarterDuration730415000JPY
Other income IFRSPrior1QuarterDuration153965000JPY
Other income IFRSCurrentQuarterDuration123339000JPY
Other expenses IFRSPrior1QuarterDuration47410000JPY
Other expenses IFRSCurrentQuarterDuration922098000JPY
Operating profit loss IFRSPrior1QuarterDuration5078877000JPY
Operating profit loss IFRSCurrentQuarterDuration-521677000JPY
Finance income IFRSPrior1QuarterDuration257195000JPY
Finance income IFRSCurrentQuarterDuration210201000JPY
Finance costs IFRSPrior1QuarterDuration299438000JPY
Finance costs IFRSCurrentQuarterDuration713629000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1QuarterDuration146262000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentQuarterDuration29323000JPY
Profit loss before tax IFRSPrior1QuarterDuration5182896000JPY
Profit loss before tax IFRSCurrentQuarterDuration-995781000JPY
Income tax expense IFRSPrior1QuarterDuration827076000JPY
Income tax expense IFRSCurrentQuarterDuration422231000JPY
Profit loss IFRSPrior1QuarterDuration4355820000JPY
Profit loss IFRSCurrentQuarterDuration-1418012000JPY
Profit loss attributable to owners of parent IFRSPrior1QuarterDuration1661679000JPY
Profit loss attributable to owners of parent IFRSCurrentQuarterDuration-1124381000JPY
Profit loss attributable to non controlling interests IFRSPrior1QuarterDuration2694140000JPY
Profit loss attributable to non controlling interests IFRSCurrentQuarterDuration-293631000JPY
Basic earnings loss per share IFRSPrior1QuarterDuration34.99
Basic earnings loss per share IFRSCurrentQuarterDuration-22.49
Diluted earnings loss per share IFRSPrior1QuarterDuration34.88
Diluted earnings loss per share IFRSCurrentQuarterDuration-22.49
Profit loss IFRSPrior1YTDDuration4014074000JPY
Profit loss IFRSCurrentYTDDuration-73850000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration897349000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration3312725000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration4925000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass
balance sheet identityconsolidated 2024-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-06-30pass